[In Vitro Identification and Characteristics of CD34 Leukemia Stem Cell in t(8;21) Acute Myeloid Leukemia].

Objective: To preliminarily identify the existence of CD34 leukemia stem cell (LSC) in t(8;21) acute myeloid leukemia (AML) by in vitro test.

Methods: Bone marrow samples collected from newly diagnosed t(8;21) AML patients were tested. LinCD34 CD38(abbreviation, CD34CD38), LinCD34CD38 (abbreviation, CD34CD38) and LinCD34CD38CD45SSC(abbreviation, CD34"LSC") cell fractions were gated by flow cytometry after staining with fluorescent antibodies.

PRAME Gene Copy Number Variation Is Related to Its Expression in Multiple Myeloma.

Multiple myeloma (MM) patients commonly present abnormal expression of cancer-testis antigens, which may serve as immunotherapeutic targets and prognostic factors. We previously reported that preferentially expressed antigen of melanoma (PRAME) overexpression in bone marrow mononuclear cells is related to progression in MM patients treated with non-bortezomib-containing regimens. The mechanism underlying variations in PRAME expression remains unknown.

Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes.

Preferentially expressed antigen of melanoma (), a tumor-associated antigen, is overexpressed in a variety of hematologic malignancies with a great variation in expression. The majority of patients with acute myeloid leukemia () 1-eight-twenty one () AML and a certain number of myelodysplastic syndromes (MDS) have an abnormally high increase in expression level. The landscape of methylation requires evaluation in order to determine the most relevant sites and the exact association of its methylation with expression level and type of disease.

PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy.

To investigate the prognostic value of PRAME expression in pediatric acute lymphoblastic leukemia(ALL), we measured PRAME transcript levels at diagnosis in 191 patients(146 B-ALL; 45T-ALL)receiving chemotherapy only. PRAME overexpression was defined as transcript levels higher than 0.30%, which is the upper limit of normal bone marrow and the optimal cutoff value derived from ROC curve analysis.